Clinical Capital Conversations

Welcome to Clinical Capital Conversations! Join host Dr. Peter M. Kovacs, a clinical research pioneer and global investor, as he explores the intersection of science and strategic investment. Discover what it takes to transform medical innovation into scalable impact.Each episode features unfiltered conversations with clinical research leaders, biotech/medtech founders, VCs, and policymakers. Peter shares his firsthand experience, from building agile clinical trial networks to investing in disruptive health tech across Asia and Europe.

Clinical Capital Conversations is a business podcast hosted by Dr. Peter M. Kovacs, with 18 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Dr. Peter M. Kovacs hosts Clinical Capital Conversations, a business show with 18 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #18

  EP18 - FemTech Is Not a Trend, It Is a Clinical Correction

  Feb 12, 202637 minS0

  <p>FemTech is often framed as a market trend. In this episode of “Clinical Capital Conversations”, Dr. Peter M. Kovacs explains why it is actually a long-overdue clinical correction.</p><p>Together with Roswitha Verwer, Founder and CEO of “YON E”, and Muskaan Bhan, Chief Clinical Officer, this conversation explores why women were historically excluded from clinical trials, how biased data still shape healthcare AI, and why continuous measurement is changing medicine.</p><p>This episode is for investors, founders, and healthcare leaders who care about execution, responsibility, and long-term impact, not shortcuts.</p><p><br></p><p>Timecode:</p><p><br><...

  ListenShow Notes
• 

  Episode #17

  EP17 - The Real Risk Is Execution: What Investors Miss When They Fund Science Without Systems

  Feb 5, 202633 minS0

  <p>In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs sits down with Roswitha Verwer (YONE) and Karoly Szanto to unpack what most investors miss in early-stage health innovation: execution is the moat.</p><p>YONE delivered the majority of a 12-month roadmap in 6 months. We break down how it happened, what systems made it possible, and why femtech fundraising is still biased even when the operating metrics are strong.</p><p>What we cover:</p><p>How to build vendor communication into contracts and timelines</p><p>Running a high-performance global team without losing control</p><p>...

  ListenShow Notes
• 

  Episode #16

  EP16 - The Co-Investor Question That Determines Everything in Biotech and Medtech

  Jan 28, 202620 minS0

  <p>This is a continuation of our main conversation on what it takes to turn medical innovation into scalable impact.</p><p>In this episode, Dr. Peter M. Kovacs sits down with Károly Szántó and Thijmen Meijer to unpack the co-investor question that determines everything in biotech and medtech.</p><p>If you are building or funding early-stage life sciences, this is the uncomfortable truth: the cap table is a governance system. The wrong co-investors can slow execution, distort milestones, and burn capital. The right co-investors create speed, trust, and real de-risk.</p><p>What we cover:</p><p>W...

  ListenShow Notes
• 

  Episode #15

  EP15 - Europe Has the Science. Asia Has the Capital. The Missing Layer Is Execution.

  Jan 22, 202654 minS0

  <p>Europe has elite science. Asia has a capital. So why do so many European university spinouts never reach venture readiness or exits?</p><p>In this episode, Dr. Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer about the real gaps that block deep tech startups, especially in Central and Eastern Europe, and what a modern support model looks like.</p><p>What we cover:</p><p>Why most spinouts never become VC fundable</p><p>The commercialization gap between research and markets</p><p>Mindset, team design, and why the founder is not always the CEO...

  ListenShow Notes
• 

  Episode #14

  EP14 - The Operating System Behind Breakthroughs: Why Venture Studios, Focus, and Execution Decide Outcomes in Healthcare

  Jan 8, 202624 minS0

  <p>In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs speaks with Károly Szántó about venture studios, calculated risk, and what it really takes to turn promising innovation into execution.</p><p>We cover:</p><p>How a non-linear career becomes a competitive advantage</p><p>Why focus beats speed in early-stage venture building</p><p>The difference between high risk and calculated risk</p><p>What university spinouts are missing, and how to fix it through market partnership</p><p>How ecosystems change through examples, not speeches</p><p>What investors should do diligence to avo...

  ListenShow Notes

Recent guests on Clinical Capital Conversations. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.